abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL’s income-focused strategy relies on net realized gains, supporting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results